微小核糖核酸-29a做為臨床生物標誌在代謝相關脂肪性肝病與肝癌的新進展

Advanced understandings of microRNA-29a in Metabolic Associated Fatty Liver Disease (MAFLD) and Hepatocellular Carcinoma (HCC)

非酒精性脂肪肝病是慢性肝病的常見原因，範圍從脂肪變性到脂肪性肝炎和肝纖維化，近來，代謝相關脂肪性肝病做為更為廣泛的概念被提出來以取代非酒精性脂肪肝病。肝細胞中的脂毒性、氧化壓力升高和庫佛氏細胞發炎介質的激活，以及活化肝星狀細胞的纖維化途徑都可導致代謝相關脂肪性肝病的發展，甚至與肝癌的發生有密切關係。非編碼的微小核糖核酸在代謝相關脂肪性肝病以及肝癌的代謝失調和發炎信號傳遞已及其朝向更嚴重階段的進展中扮演重要的角色。值得注意的是，近年來許多研究強調了微小核糖核酸-29a表現量在代謝相關脂肪性肝病以及肝癌的臨床重要性。在此，我們回顧了微小核糖核酸-29a在臨床情境的最新進展，以及強調其未來發展成臨床生物指標的潛力。

Nonalcoholic fatty liver disease (NAFLD) is a prevalent cause of chronic liver disease that can range from steatosis to steatohepatitis and liver fibrosis. Recently, metabolic associated fatty liver disease (MAFLD) has been proposed as a novel concept to replace NAFLD. The development of NAFLD is linked to lipotoxicity, elevated oxidative stress and activation of inflammatory mediators in Kupffer cells in hepatocytes, and activation of the fibrotic pathway in hepatic stellate cells These factors can lead to the occurrence of NAFLD and are even closely related to the occurrence of hepatocellular carcinoma (HCC). Noncoding microRNAs (miRs) also play an important role in metabolic dysregulation, inflammatory signaling and disease progression towards more severe stages in NAFLD and HCC. In recent years, many studies have highlighted the clinical importance of miR-29a expression in NAFLD and HCC. Here, we review recent advances in miR-29a in clinical settings and highlight its potential as a clinical biomarker for future development.